Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sight Sciences Inc (NQ: SGHT )

4.025 +0.015 (+0.37%)
Streaming Delayed Price Updated: 2:36 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences Inc

< Previous 1 2 3 4 5 6 Next >
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team 
From Sight Sciences, Inc.
Via GlobeNewswire
A Preview Of Sight Sciences's Earnings
Via Benzinga
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures 
From Sight Sciences, Inc.
Via GlobeNewswire
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
From Sight Sciences, Inc.
Via GlobeNewswire
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
Lions Gate Entertainment, DexCom, Yelp And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Sight Sciences Announces 1,000th TearCare® Customer Installation
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) 
From Sight Sciences, Inc.
Via GlobeNewswire
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
Company Also Announces CFO Transition 
From Sight Sciences, Inc.
Via GlobeNewswire
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
From Sight Sciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. 
Via Benzinga
Dow Turns Higher; Nasdaq Jumps Over 200 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 60 points on Friday. 
Via Benzinga
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program. 
Via Benzinga
Nasdaq Surges 100 Points; Crude Oil Rises Sharply
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining 100 points on Friday. 
Via Benzinga
US Stocks Mixed Following Thursday's Rally; Dow Drops 50 Points
U.S. stocks traded mixed this morning on Friday, after the Dow Jones jumped 1,200 points in the previous session. 
Via Benzinga
Sight Sciences Reports Third Quarter 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.